127 related articles for article (PubMed ID: 18695355)
1. AG490, a Jak2-specific inhibitor, induces osteoclast survival by activating the Akt and ERK signaling pathways.
Kwak HB; Sun HM; Ha H; Lee JH; Kim HN; Lee ZH
Mol Cells; 2008 Nov; 26(5):436-42. PubMed ID: 18695355
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors induce osteoclast survival by activating the Akt pathway.
Kwak HB; Lee MS; Kim HS; Cho HJ; Kim JW; Lee ZH; Oh J
Biochem Biophys Res Commun; 2008 Dec; 377(1):1-6. PubMed ID: 18492488
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis.
Matsumoto T; Nagase Y; Iwasawa M; Yasui T; Masuda H; Kadono Y; Nakamura K; Tanaka S
Arthritis Rheum; 2011 Dec; 63(12):3908-17. PubMed ID: 21898348
[TBL] [Abstract][Full Text] [Related]
4. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
5. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.
Rahmani M; Anderson A; Habibi JR; Crabtree TR; Mayo M; Harada H; Ferreira-Gonzalez A; Dent P; Grant S
Blood; 2009 Nov; 114(20):4507-16. PubMed ID: 19773546
[TBL] [Abstract][Full Text] [Related]
6. Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1.
Fukuda A; Hikita A; Wakeyama H; Akiyama T; Oda H; Nakamura K; Tanaka S
J Bone Miner Res; 2005 Dec; 20(12):2245-53. PubMed ID: 16294277
[TBL] [Abstract][Full Text] [Related]
7. TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways.
Cicek M; Vrabel A; Sturchio C; Pederson L; Hawse JR; Subramaniam M; Spelsberg TC; Oursler MJ
PLoS One; 2011 Mar; 6(3):e17522. PubMed ID: 21423731
[TBL] [Abstract][Full Text] [Related]
8. Concomitant inactivation of the epidermal growth factor receptor, phosphatidylinositol 3-kinase/Akt and Janus tyrosine kinase 2/signal transducer and activator of transcription 3 signalling pathways in cardiotoxin III-treated A549 cells.
Su JC; Lin KL; Chien CM; Chuang PW; Chang LS; Lin SR
Clin Exp Pharmacol Physiol; 2010 Aug; 37(8):833-40. PubMed ID: 20456425
[TBL] [Abstract][Full Text] [Related]
9. IL-1alpha stimulation of osteoclast survival through the PI 3-kinase/Akt and ERK pathways.
Lee ZH; Lee SE; Kim CW; Lee SH; Kim SW; Kwack K; Walsh K; Kim HH
J Biochem; 2002 Jan; 131(1):161-6. PubMed ID: 11754748
[TBL] [Abstract][Full Text] [Related]
10. A medium-chain fatty acid, capric acid, inhibits RANKL-induced osteoclast differentiation via the suppression of NF-κB signaling and blocks cytoskeletal organization and survival in mature osteoclasts.
Kim HJ; Yoon HJ; Kim SY; Yoon YR
Mol Cells; 2014 Aug; 37(8):598-604. PubMed ID: 25134536
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of JAK2 by AG490 promotes TNF-α-induced apoptosis by inhibiting autophagy in MC3T3-E1 cells.
Ni Y; Zhang H; Zhang J; Li Z; Li Z
Pharmazie; 2020 Jun; 75(6):255-260. PubMed ID: 32539921
[TBL] [Abstract][Full Text] [Related]
12. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line.
Nuutinen U; Postila V; Mättö M; Eeva J; Ropponen A; Eray M; Riikonen P; Pelkonen J
Exp Cell Res; 2006 Feb; 312(3):322-30. PubMed ID: 16309671
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of the JAK2/PI3K-mediated signaling activation is involved in Taiwan cobra cardiotoxin III-induced apoptosis of human breast MDA-MB-231 cancer cells.
Lin KL; Su JC; Chien CM; Chuang PW; Chang LS; Lin SR
Toxicon; 2010 Jun; 55(7):1263-73. PubMed ID: 20144642
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Dai Y; Rahmani M; Pei XY; Khanna P; Han SI; Mitchell C; Dent P; Grant S
Blood; 2005 Feb; 105(4):1706-16. PubMed ID: 15494423
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
Hahn M; Li W; Yu C; Rahmani M; Dent P; Grant S
Mol Cancer Ther; 2005 Mar; 4(3):457-70. PubMed ID: 15767555
[TBL] [Abstract][Full Text] [Related]
17. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2.
Xu R; Chen J; Cong X; Hu S; Chen X
J Cell Biochem; 2008 Jan; 103(1):256-69. PubMed ID: 17497701
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.
Kawabata T; Tanimura S; Asai K; Kawasaki R; Matsumaru Y; Kohno M
J Biol Chem; 2012 Mar; 287(13):10289-10300. PubMed ID: 22270368
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim.
Houde N; Chamoux E; Bisson M; Roux S
J Biol Chem; 2009 Aug; 284(35):23397-404. PubMed ID: 19574221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
